Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In vitro fertilization devices

This article was originally published in The Gray Sheet

Executive Summary

Makers of IVF devices already in commercial distribution will be allowed to continue marketing the products provided that they have submitted a 510(k) for each device marketed in the U.S. within 60 days, FDA says in a letter posted on its website Feb. 19. Additionally, makers of the devices, which were reclassified into either Class II or Class I in October ("The Gray Sheet" Sept. 14, 1998, p. 16), must register their products and list their establishments with the agency. Adherence to the quality system regulation and "other pertinent FDA regulations," such as medical device reporting, labeling and corrections and removals, also is required. Firms in compliance with the stipulations and the reclassification document may continue marketing their devices until FDA determines that the products are substantially equivalent. Devices found not substantially equivalent will require a premarket application approval to be approved before marketing may resume, the agency says

You may also be interested in...

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.

Sandoz Pledges Price Stability Amid Coronavirus

Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.

Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex

T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts